Delcath Systems to Participate at Upcoming Virtual Investor Conferences

Rhea-AI Summary

Delcath Systems (DCTH), an interventional oncology firm, has announced its participation in upcoming virtual investor conferences. Notable events include the BTIG Virtual MedTech Conference on February 18 at 1:00 PM ET and the SVB Leerink's Annual Global Healthcare Conference from February 22 to 26, which will consist of one-on-one meetings only. The company's investigational product, HEPZATO KIT, targets rare liver cancers. It is currently not FDA-approved in the U.S. but is marketed in Europe as CHEMOSAT, where it has received CE Mark certification.

NEW YORK, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will participate at these upcoming virtual investor conferences:

• The BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Thursday, February 18 at 1:00 pm (ET)
  • Webcast Link: https://wsw.com/webcast/btig3/dcth/1715371

• SVB Leerink’s 10th Annual Global Healthcare Conference February 22 – 26
  • 1x1 meetings only

For more information or to schedule a one-on-one meeting with management, please contact your conference representative or James@HaydenIR.com.

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO KIT has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.

Contact:

Delcath Investor Relations

Email: investorrelations@delcath.com

Hayden IR

James Carbonara 
(646)-755-7412 
james@haydenir.com

FAQ

What are the upcoming conferences for Delcath Systems (DCTH)?

Delcath Systems will participate in the BTIG Virtual MedTech Conference on February 18, 2021, and the SVB Leerink's Annual Global Healthcare Conference from February 22 to 26, 2021.

What is Delcath Systems (DCTH) known for?

Delcath Systems focuses on interventional oncology, particularly in the treatment of primary and metastatic liver cancers.

Is HEPZATO KIT approved in the U.S.?

No, HEPZATO KIT has not been approved by the FDA for sale in the U.S.

What is CHEMOSAT and where is it marketed?

CHEMOSAT is the European trade name for Delcath's hepatic delivery system for melphalan, which has received CE Mark certification and is used in major medical centers.